Featured Research

from universities, journals, and other organizations

Three biomarkers in spinal fluid appear helpful to classify patients with Alzheimer's disease

Date:
August 10, 2010
Source:
JAMA and Archives Journals
Summary:
A "signature" consisting of three biomarkers in the cerebrospinal fluid was present in 90 percent of patients who had been diagnosed with Alzheimer's disease but also was found in more than one-third of cognitively normal older adults, according to a new report.

A "signature" consisting of three biomarkers in the cerebrospinal fluid was present in 90 percent of patients who had been diagnosed with Alzheimer's disease but also was found in more than one-third of cognitively normal older adults, according to a report in the August issue of Archives of Neurology.

"The initiation of the Alzheimer's disease pathogenic process is typically unobserved and has been thought to precede the first symptoms by 10 years or more," the authors write as background information in the article. "Therefore, demonstrating that Alzheimer's disease biomarkers, such as cerebrospinal fluid beta-amyloid protein 1-42 (CSF Aß1-42), total CSF tau protein and CSF phosphorylated tau181P (P-Tau181P) protein concentrations are true indicators of the pathogenic process at an early stage is a major challenge."

Geert De Meyer, Ph.D., of Ghent University, Ghent, Belgium, and colleagues in the Alzheimer's Disease Neuroimaging Initiative analyzed data from 114 older adults who were cognitively normal, 200 who had mild cognitive impairment and 102 who had Alzheimer's disease. They first modeled the data from all participants, without considering their cognitive status, to identify profiles that had different levels of three biomarkers: CSF Aß1-42, total CSF tau protein and P-Tau181P. One profile or signature was presumed to be associated with Alzheimer's disease while the other matched a "healthy" status.

When these profiles were applied to the data in the subgroups, the Alzheimer's disease signature was found in 90 percent of those with Alzheimer's disease, 72 percent of those with mild cognitive impairment and 36 percent of those who were cognitively normal.

"Results were validated on two other data sets," the authors write. "In one study consisting of 68 autopsy-confirmed Alzheimer's disease cases, 64 of 68 patients (94 percent sensitivity) were correctly classified with the Alzheimer's disease feature. In another data set with patients (n=57) with mild cognitive impairment followed up for five years, the model showed a sensitivity of 100 percent in patients progressing to Alzheimer's disease."

The results suggest that this signature of biomarkers -- developed independently of data on clinical diagnosis of Alzheimer's disease -- can correctly classify patients with the condition. "The unexpected presence of the Alzheimer's disease signature in more than one-third of cognitively normal subjects suggests that Alzheimer's disease pathology is active and detectable earlier than has heretofore been envisioned," the authors conclude. "Thus, taken together, these data provide further support for the view that revision of current diagnostic criteria for Alzheimer's disease is needed, or at least as far as early-stage Alzheimer's disease is concerned."

This work was supported mainly by an ADNI grant.

Editorial: Biomarkers Aid Diagnosis of Alzheimer's Disease

"The article by De Meyer et al in this month's issue of the Archives presents a novel method of analyzing cerebrospinal fluid (CSF) biomarker data and determining how these data map onto the clinical diagnoses of Alzheimer's disease, mild cognitive impairment and healthy control subjects," write A. Zara Herskovits, M.D., Ph.D., of Brigham and Women's Hospital, and John H. Growdon, M.D., of Massachusetts General Hospital, Boston, in an accompanying editorial.

"To date, cerebrospinal fluid analyses have not been a routine component of assessment and care for patients with cognitive impairments and suspected Alzheimer's disease in the United States. There is now ample evidence that these measurements have value; physicians need to formulate when and how to incorporate cerebrospinal fluid measurements into their practice," they write.

"Gazing into the future when there are neuroprotective medications for Alzheimer's disease, we can envision a recommendation that cerebrospinal fluid analyses be implemented as a screening test to identify clinically healthy individuals at risk for mild cognitive impairment and Alzheimer's disease. The information gained would enable early application of treatments to delay onset of symptoms or slow progression of cognitive impairments."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal References:

  1. De Meyer et al. Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. Archives of Neurology, 2010; 67 (8): 949 DOI: 10.1001/archneurol.2010.179
  2. A. Zara Herskovits and John H. Growdon. Sharpen That Needle. Arch Neurol., 2010;67(8):918-920 DOI: 10.1001/archneurol.2010.151

Cite This Page:

JAMA and Archives Journals. "Three biomarkers in spinal fluid appear helpful to classify patients with Alzheimer's disease." ScienceDaily. ScienceDaily, 10 August 2010. <www.sciencedaily.com/releases/2010/08/100809161132.htm>.
JAMA and Archives Journals. (2010, August 10). Three biomarkers in spinal fluid appear helpful to classify patients with Alzheimer's disease. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2010/08/100809161132.htm
JAMA and Archives Journals. "Three biomarkers in spinal fluid appear helpful to classify patients with Alzheimer's disease." ScienceDaily. www.sciencedaily.com/releases/2010/08/100809161132.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) — An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) — Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) — Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) — It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins